Literature DB >> 11317188

Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials.

C Y Hsu1.   

Abstract

OBJECTIVE: It remains controversial whether non-malignant 'benign' hypertension causes renal dysfunction. The effect of lowering blood pressure on the incidence of renal dysfunction among patients with non-malignant hypertension is not clear. This meta-analysis was conducted to determine whether antihypertensive drug therapy reduces the incidence of renal dysfunction in patients with non-malignant hypertension.
METHODS: Randomised, controlled trials of antihypertensive drug therapy of more than 1 year duration that reported renal dysfunction as an outcome were identified through MEDLINE search and literature review. A random effects model was used to obtain summary estimates.
RESULTS: Ten trials were identified, involving 26, 521 individuals and 114 000 person-years. All excluded subjects with advanced baseline renal disease. Definition of renal dysfunction outcome varied among trials but within each trial was applied similarly to both treatment and control groups. Drug treatment consisted mostly of diuretics and adrenergic blockers. Overall, treated patients had lower blood pressure and fewer cardiovascular events. There were a total of 317 cases of renal dysfunction. Patients randomised to antihypertensive therapy (or more intensive therapy) did not have a significant reduction in their risk of developing renal dysfunction (relative risk = 0.97; 95% confidence interval (CI) 0.78-1.21; P = 0.77).
CONCLUSIONS: Among patients with non-malignant hypertension enrolled in randomised trials, treated patients did not have a lower risk of renal dysfunction. The 95% CI suggests that a 25% or more true protective effect of antihypertensive drugs is unlikely.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317188     DOI: 10.1038/sj.jhh.1001128

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  9 in total

1.  Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population.

Authors:  Naoki Shiraishi; Kenichiro Kitamura; Yukimasa Kohda; Kunitoshi Iseki; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2013-07-06       Impact factor: 2.801

2.  Hypertension after kidney donation: Incidence, predictors, and correlates.

Authors:  Otto A Sanchez; Laine K Ferrara; Sarah Rein; Danielle Berglund; Arthur J Matas; Hassan N Ibrahim
Journal:  Am J Transplant       Date:  2018-04-06       Impact factor: 8.086

Review 3.  Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder.

Authors:  Jeffrey B Kopp
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-05       Impact factor: 2.894

4.  Patterns of End-Stage Renal Disease Caused by Diabetes, Hypertension, and Glomerulonephritis in Live Kidney Donors.

Authors:  S Anjum; A D Muzaale; A B Massie; S Bae; X Luo; M E Grams; K L Lentine; A X Garg; D L Segev
Journal:  Am J Transplant       Date:  2016-07-12       Impact factor: 8.086

5.  Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial.

Authors:  Carmen A Peralta; Leslie A McClure; Rebecca Scherzer; Michelle C Odden; Carole L White; Michael Shlipak; Oscar Benavente; Pablo Pergola
Journal:  Circulation       Date:  2016-01-13       Impact factor: 29.690

6.  Do inhibitors of the rennin-angiotensin system prevent chronic kidney disease?

Authors:  Brian Rayner
Journal:  Cardiovasc J Afr       Date:  2010 Jan-Feb       Impact factor: 1.167

7.  Blood pressure and age-related GFR decline in the general population.

Authors:  Bjørn O Eriksen; Vidar T N Stefansson; Trond G Jenssen; Ulla D Mathisen; Jørgen Schei; Marit D Solbu; Tom Wilsgaard; Toralf Melsom
Journal:  BMC Nephrol       Date:  2017-02-28       Impact factor: 2.388

8.  Postdonation eGFR and New-Onset Antihypertensive Medication Use After Living Kidney Donation.

Authors:  Krista L Lentine; Courtenay M Holscher; Abhijit S Naik; Ngan N Lam; Dorry L Segev; Amit X Garg; David Axelrod; Huiling Xiao; Macey L Henderson; Allan B Massie; Bertram L Kasiske; Gregory P Hess; Chi-Yuan Hsu; Meyeon Park; Mark A Schnitzler
Journal:  Transplant Direct       Date:  2019-07-25

9.  Does established vascular kidney disease exist?

Authors:  Nicolás Roberto Robles; Francesco Fici; Elif Ari Bakir; Guido Grassi
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-31       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.